English translation

Summary of Financial Results
for the Third Quarter of Fiscal Year Ending December 31, 2013
[Japanese GAAP] (Non-Consolidated)
November 8, 2013
Company Name

SymBio Pharmaceuticals Limited

Listing: Tokyo Securities Exchange

Securities Code4582

URL http://www.symbiopharma.com/

Representative

Representative Director, President andChief Executive Officer

Fuminori Yoshida

Contact Person

Executive Vice President, CFO andHead of Corporate Division

Takashi Shimomura

TEL 03(5472)1125

Scheduled Date to File
Quarterly Report

November 11, 2013

Date of Dividend
Payment (plan)－Supplementary Materials for theQuarterly Financial Results:

Yes

No

Holding of Quarterly Earnings
Performance review:

Yes

No

(millions of yen – rounded down, unless otherwise stated）
1. Business Results for the First Three Quarters of FY 2013 (January 1, 2013 to September 30, 2013)(1) Operating Results (cumulative)(percentage indicates year-on-year changes)
Quarterly Net IncomeNet Sales
Operating Income (loss) Ordinary Income (loss)(loss)
millions of yen%millions of yen%millions of yen%millions of yen%

1,323
1,518

(12.8)
16.2(1,192)(1,238)－－(1,187)(1,256)－－(1,190)(1,259)－－3Q FY 2013
3Q FY 2012

Quarterly Net Income(loss) per share

Diluted Net Income pershare

YenYen3Q FY 2013(52.93)－
3Q FY 2012(65.84)－Note: Despite the issuance of stock acquisition rights, information in connection with diluted quarterly net profit per share notdisclosed due to quarterly net loss per share.
(2) Financial Position

3Q FY 2013 (as of September 30,2013)

FY 2012 (as of December 31, 2012)

Total Assets

Net Assets

Equity Ratio

Net Assets per Sharemillions of yen

millions of yen%Yen

5,214

5,005

94.5

213.70

5,502

4,899

88.6

254.71(Reference) Net assets excluding subscription rights to shares:
3Q FY 2013 (as of September 30, 2013)
FY 2012 (as of December 31, 2012)

4,926 million yen
4,872 million yen

2. Dividends

FY 2012FY 2013
FY 2013 (Forecast)

1st Quarter
Yen－－

Annual Dividend per Share
2nd Quarter
3rd Quarter
Fiscal Year End
Yen
Yen
Yen
0.00
－0.00
0.00
－0.00

Full Year
Yen
0.00
0.00

English translation

Yes ・ No

Note: Revision to dividends forecast recently announced:

3. Earnings Forecast for FY 2013 (January 1, 2013 to December 31, 2013)
OperatingIncome (loss)

Net Sales

Full Year(percentage indicates year-on-year change)
Net Income (loss)
Net Income (loss)
per share

Ordinary
Income (loss)

millions ofyen%millions ofyen%millions ofyen%millions of
yen%

Yen

1,563

(20.1)(1,743)－(1,749)－(1,753)－(76.10)

Yes ・ No

Note: Revision to earnings forecast recently announced:

Notes:(1) Application of special accounting treatment inpreparation of quarterly financial reports:

Yes ・ No

(2) Changes in accounting policies, accounting estimates and restatements after error correction(a) Changes in accounting polices due to revisionof accounting standards:

Yes ・ No(b) Changes in accounting polices due to otherreason(s):Yes(c) Changes in accounting estimates:

Yes ・ No(d) Restatement after error correction:

Yes ・ NoNo

(3) Number of shares outstanding (common stock)(i) Number of shares outstanding at end of theperiod (including treasury stock)(ii) Number of shares of treasury stock at endof the period(iii) Average number of shares during the period(cumulative)

3Q FY 2013

23,052,157 shares

FY 2012

19,130,900 shares

3Q FY 201375 shares

FY 201275 shares

3Q FY 2013

22,495,451 shares

3Q FY 2012

19,130,825 shares* The status of quarterly review
The review of quarterly financial statements as required by the Financial Instruments and Exchange Act is proceeding as of thedate of this disclosure document.
* Explanation regarding the appropriate use of earnings forecasts and other matters
All forecasts presented in this document including earnings forecasts are based on the information currently available tomanagement and assumptions judged by management to be reasonable. Actual results may differ substantially from the forecasts
contained herein due to various factors. Regarding the assumptions on which the earnings forecasts are based and their usage,
please refer to “1. Qualitative Information Concerning Quarterly Financial Results, (3) Qualitative information concerning
earnings forecasts” on Page 2 of the following attachment.

SymBio Pharmaceuticals Limited (4582) Summary of Financial Results [Japanese GAAP] (Non-consolidated)
Results for the Third Quarter of Fiscal Year Ending December 31, 2013

Index of Attachment
1. Qualitative Information Concerning Quarterly Financial Results ……………………………………………………

1(1) Qualitative Information Concerning Business Results ……………………………………………………………

1(2) Qualitative Information Concerning Financial Position …………………………………………….……………

2(3) Qualitative Information Concerning Earnings Forecasts ………………………………………………….………

2

2. Quarterly Financial Statements …………………………………………………………………………………..……

3(1) Balance Sheets ……………………………………………………………………………………………………..

3(2) Statements of Operations…………………………………………………………………………….……………

5

Statements of Operations (cumulative) …………………………………………………………………………

5(3) Notes Concerning Going Concern Assumption……………………………………………………………………

6(4) Notes Concerning Significant Changes in Shareholders’ Equity ………………………………….…………….

6

SymBio Pharmaceuticals Limited (4582) Summary of Financial Results [Japanese GAAP] (Non-consolidated)
Results for the Third Quarter of Fiscal Year Ending December 31, 20131. Qualitative Information Concerning Quarterly Financial Results(1) Qualitative Information Concerning Business Results
Progress in the Company’s business for the third quarter of FY 2013:(i) Domestic[SyB L-0501 (generic name: bendamustine hydrochloride, trade name: TREAKISYM®)]
The Company sells an anticancer drug (SyB L-0501) in Japan through its business partner, Eisai Co., Ltd. (Eisai), for theindications of refractory/relapsed indolent non-Hodgkin’s lymphoma (NHL) and mantle cell lymphoma (MCL).
The Company continues to conduct clinical trials for TREAKISYM® in additional indications.
Regarding the Phase II clinical trial (collaborative trial in Japan and South Korea) for refractory/relapsed aggressive
NHL, despite the completion of the analysis and evaluation of clinical trial data, the Company temporarily suspended theapplication for approval of the indication which it originally planned to submit in the previous fiscal year, based on theresults of a pre-application meeting and ongoing discussions with the Pharmaceuticals and Medical Devices Agency(PMDA), and continuing discussions with the agency.
For the frontline Low-grade NHL and MCL indications, Phase II patient enrollment was completed in March, 2013.
For refractory/relapsed multiple myeloma (r/r MM), the Company had been conducting the multicenter open-label trial in
r/r MM patients with bendamustine as amonotherapy in collaboration with Eisai since December, 2011. While safety of thedrug has been established in this study following the treatment of 17 patients at 90 mg/m2, the study has failed to achieve
the expected level of efficacy as a single agent. SymBio and Eisai will re-examine the development strategy for r/r MM in
Japan in relation to the development status of TREAKISYM® in the US and EU where it is being used in combination withother anticancer drugs.
For the chronic lymphocytic leukemia (CLL) indication, enrollment of patients for the Phase II clinical trial is ongoingwith the first patient enrolled in May, 2013. TREAKISYM® received orphan drug designation in Japan from the Ministryof Health, Labour and Welfare (MHLW) in June, 2012.
In addition, the Company received a notice of release from the special drug use results survey in March, 2013, anextensive survey which was a pre-condition for approval of the r/r low-grade NHL and MCL indications by the MHLW.
[SyB L-1101 (intravenous form)/C-1101 (oral form) (generic name: rigosertib)]
Enrollment of high-risk myelodysplastic symdrome (MDS) patients in the Phase I clinical trial for the IV form ofrigosertib (SyB L-1101) continues, with initiation of patient enrollment in the Phase 1 trial for the oral form of rigosertib(SyB C-1101) in March, 2013.
[SyB D-0701]
In January 2013, the Company completed its Phase II clinical trial for SyB D-0701 (a transdermal antiemetic patch) for theindication of radiotherapy-induced nausea and vomiting. However, since the results failed to show the expected efficacy, nofurther development of this patch is under consideration at this time.
(ii) Overseas
Sales of SyB L-0501 are doing well. The drug is being marketed in Taiwan through the Taiwanese company,
InnoPharmax Inc., and in Singapore and South Korea through local subsidiaries of Eisai Co., Ltd.
(iii) Fund Procurement
The Company passed a resolution on December 27, 2012 to issue the first unsecured convertible bond with stockacquisition rights (total issue price: 1 billion yen) with Whiz Healthcare PE Series 1 Investment Limited Liability
Partnership as the allottee and the 29th warrant (total issue price: 5.1 million yen; total issue price of stock when issued
through the exercise of stock acquisition rights: 500 million yen), with the aim of accelerating the development of new drugcandidates and further strengthening the pipeline. Accordingly, Whiz Healthcare PE Series 1 Investment Limited Liability
Partnership completed payment of 1,005,100 thousand yen to the Company on January 15, 2013.
In January 2013, the 29th series stock option was partially exercised and the total paid-in amount of 199,998 thousand
yen has been received.
(iv) Business Results-1-SymBio Pharmaceuticals Limited (4582) Summary of Financial Results [Japanese GAAP] (Non-consolidated)
Results for the Third Quarter of Fiscal Year Ending December 31, 2013

As a result of the above, net sales totaled 1,323,544 thousand yen (a year-on-year decrease of 12.8 %) for the third quarterof fiscal year ending December 31, 2013, following review of the current market inventory level, primarily reflecting salesof SyB L-0501 in Japan and the other Asia Pacific territories.
Selling, general and administrative expenses totaled 1,466,105 thousand yen (a year-on-year decrease of 14.9%),
including research and development (“R&D”) expenses of 815,776 thousand yen (a year-on-year decrease of 23.2 %) due tothe accrual of expenses associated with the clinical trials for multiple indications of SyB L-0501 and clinical trials orpreparations for SyB L-1101 as well as other selling, general and administrative expenses of 650,328 thousand yen (a yearon-year decrease of 1.7 %).
Thus, we posted an operating loss of 1,192,955 thousand yen for the first nine months ended September 30, 2013
(operating loss of 1,238,704 thousand yen for the same period in the previous fiscal year). In addition, the Company
recorded a total of 12,994 thousand yen as non-operating expenses, primarily comprising commission fees and stock
issuance costs, and recorded 18,041 thousand yen as non-operating income, primarily comprising interest income and profit
on securities sold which led to an ordinary loss of 1,187,907 thousand yen (ordinary loss of 1,256,757 thousand yen for thesame period in the previous fiscal year) and net loss of 1,190,757 thousand yen (net loss of 1,259,647 thousand yen for thesame period in the previous fiscal year).
Segment information has been omitted in the summary of business results given that the Company operates withina single
segment of the pharmaceutical business, including research and development of pharmaceutical drugs as well as
manufacturing, marketing and other related activities.

(2) Qualitative Information Concerning Financial Positions
Total assets as of September 30, 2013, stood at 5,214,407 thousand yen, a decrease of 287,782 thousand yen from theprevious fiscal year end. Total current assets decreased by 266,239 thousand yen from the previous fiscal year end to
5,154,383 thousand yen, primarily due to both an increase in marketable securities by 700,905 thousand yen, and decrease in
cash and deposits by 872,924 thousand yen arising from fund procurement. Total noncurrent assets stood at 60,024 thousand
yen, a decrease of 21,542 thousand yen primarily due to a decrease in long-term prepaid expenses by 13,951 thousand yen
from the previous fiscal year end.
Total liabilities decreased by 393,578 thousand yen from the previous fiscal year end to 208,654 thousand yen, primarily
due to a decrease in accounts payable by 312,017 thousand yen.
Net assets increased by 105,795 thousand yen from the previous fiscal year end to 5,005,753 thousand yen due to anincrease in capital stock and capital surplus by 621,819 thousand yen arising from fund procurement despite a net loss of
1,190,757 thousand yen. As a result, in conjunction with a decrease in liabilities, the equity ratio increased by 5.9
percentage points to 94.5% from the previous fiscal year end.

(3) Qualitative Information Concerning Earnings Forecasts
No revision has been made to the earnings forecast for FY 2013 as of the date of this document.

-2-SymBio Pharmaceuticals Limited (4582) Summary of Financial Results [Japanese GAAP] (Non-consolidated)
Results for the Third Quarter of Fiscal Year Ending December 31, 2013

2. Quarterly Financial Statements(1) Balance sheets(Unit: thousands of yen)
FY 20123Q FY 2013(as of December 31, 2012)(as of September 30, 2013)

AssetsCurrent assets
Cash and deposits
Accounts receivable-trade

4,540,022
148,0813,667,097
198,404

Marketable securities
Merchandise and finished goods

300,000
164,571

1,000,905
126,098

Prepaid expenses
Advances paid

98,192
99,03652,582
85,465

Other
Total current assets

70,71823,8305,420,623

5,154,383

Noncurrent assets
Property, plant and equipment
Buildings, net

2,637

2,493

Tools, furniture and fixtures, net

11,084

7,411

Total property, plant and equipment

13,721

9,905

SoftwareLease assets

8,324
2,540

6,504
2,054

Total intangible assets

10,864

8,558

Investments and other assets
Long-term prepaid expenses

27,646

13,695

Lease and guarantee deposits

29,334

27,865

Total investments and other assets

56,98041,560Intangible assets

Total noncurrent assets

81,56760,024

5,502,190

5,214,407

Accounts payable-trade
Accounts payable-other329,768
195,833

17,750158,934

Income taxes payable
Other

15,58857,336

8,811
20,036

Total current liabilities

598,527

205,533

1,688

1,615

Other

2,017

1,506

Total noncurrent liabilities

3,705

3,121

602,232

208,654

Total assets
Liabilities
Current liabilities

Noncurrent liabilities
Provision for retirement benefits

Total liabilities-3-SymBio Pharmaceuticals Limited (4582) Summary of Financial Results [Japanese GAAP] (Non-consolidated)
Results for the Third Quarter of Fiscal Year Ending December 31, 2013

(Unit: thousands of yen)
FY 20123Q FY 2013(as of December 31, 2012)(as of September 30, 2013)

Net assets
Shareholders' equity
Capital stock
Capital surplus
Retained earnings
Treasury stock
Total shareholders' equity
Valuation and translation adjustments
Valuation difference on available-for-salesecurities
Total valuation and translation adjustments
Subscription rights to shares
Total net assets
Total liabilities and net assets

6,024,610
5,994,610

6,646,429
6,616,429(7,146,411)(17)(8,337,169)
(17)

－

561

－

561

4,872,790-4-

4,925,671

27,167

79,5204,899,957

5,005,753

5,502,190

5,214,407

SymBio Pharmaceuticals Limited (4582) Summary of Financial Results [Japanese GAAP] (Non-consolidated)
Results for the Third Quarter of Fiscal Year Ending December 31, 2013

(2) Statements of operations (cumulative)(for the third quarter of fiscal year ending December 31, 2013)(Unit: thousands of yen)
3Q FY 2012

3Q FY 2013

(from January 1, 2012
to September 30, 2012)(from January 1, 2013
to September 30, 2013)

Net sales
Cost of sales
Gross profit
Selling, general and administrative expenses
Operating loss
Non-operating income
Interest income
Interest on securities
Profit on securities soldInterest on tax refunded
Dividends income of insurance
Foreign exchange gain
Other
Total non-operating income
Non-operating expenses
Interest expenses
Commission fee
Stock issuance cost
Foreign exchange losses
OtherTotal non-operating expenses
Ordinary loss
Extraordinary loss
Loss on disposal of fixed assets
Total extraordinary loss
Loss before income taxes
Income taxes-current
Total income taxes
Net loss

1,518,446

1,323,544

1,033,570

1,050,394

484,875

273,150

1,723,580

1,466,105(1,238,704)(1,192,955)

2,347
－

2,176
5,354

654
1,122

104
1,104－
147

4,275
172

5,547

18,041

1,275

128

24

8,107
－

8,077
4,791

15,045
320－100

23,60012,994(1,256,757)(1,187,907)

39
39(1,256,797)
2,850-5-4,853－－(1,187,907)
2,850

2,850

2,850

(1,259,647)(1,190,757)

SymBio Pharmaceuticals Limited (4582) Summary of Financial Results [Japanese GAAP] (Non-consolidated)
Results for the Third Quarter of Fiscal Year Ending December 31, 2013

(3) Notes Concerning Going Concern Assumption
None(4) Notes Concerning Significant Changes in Shareholders’ Equity
Based on the resolution at the Company’s Board of Directors Meeting held on December 27, 2012, the Company issued the1st unsecured convertible bond with stock acquisition rights and the 29th series stock option on January 15, 2013, receiving
proceeds in the amount of 1,005,100 thousand yen on the same day.
With regard to the first unsecured convertible bond with stock acquisition rights, all rights with face value of 1,000,000
thousand yen had been exercised by February 27, 2013. As for the 29th series stock option, 20 units (26,525 shares per unit)
were exercised on January 25, 2013 and proceeds of 199,998 thousand yen received.
As a result of these primary events, capital stock and capital surplus increased by 621,819 thousand yen to 6,646,429
thousand yen and 6,616,429 thousand yen, respectively, as of September 30, 2013.

-6-